An editor has performed a search and found that sufficient sources exist to establish the subject's notability. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Porfiromycin" – news · newspapers · books · scholar · JSTOR (January 2023) (Learn how and when to remove this template message)
Porfiromycin
Clinical data
Trade namesPromycin[1]
ATC code
Identifiers
  • [(4S,6S,7R,8S)-11-amino-7-methoxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
CAS Number
PubChem CID
DrugBank
ChemSpider
KEGG
ChEMBL
Chemical and physical data
FormulaC16H20N4O5
Molar mass348.359 g·mol−1
3D model (JSmol)
  • CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4C)N
  • InChI=1S/C16H20N4O5/c1-6-10(17)13(22)9-7(5-25-15(18)23)16(24-3)14-8(19(14)2)4-20(16)11(9)12(6)21/h7-8,14H,4-5,17H2,1-3H3,(H2,18,23)/t7-,8+,14+,16-,19?/m1/s1
  • Key:HRHKSTOGXBBQCB-VFWICMBZSA-N

Porfiromycin is an N-methyl derivative of the antineoplastic antibiotic, mitomycin C, which is isolated from various Streptomyces bacterial species.[2] As an antineoplastic agent, it is under investigation for the treatment of cancer, particularly head and neck cancer.[1]

Porfiromycin works by generating oxygen radicals and alkylating DNA, resulting in interstrand cross-links and single-strand breaks. This inhibits DNA synthesis and leads to the death of cancer cells. It has a higher toxicity towards hypoxic cells, making it an attractive option for cancer treatment.[2]

Porfiromycin can increase the risk of methemoglobinemia when taken with certain medications.[1] It belongs to the class of compounds known as mitomycins, which are characterized by their aziridine ring linked to a 7-amino-6-methyl-cyclohexa[b]pyrrolizine-5,8-dione structure.[1]

References

  1. ^ a b c d e "Porfiromycin". Retrieved January 8, 2022.
  2. ^ a b c "Porfiromycin (Code C763)". Retrieved January 8, 2022.
Categories